Search results for: pMYs-GFP Retroviral Vector
#29554931 // Save this To Up
Clinical evaluation of outdoor cats exposed to ectoparasites and associated risk for vector-borne infections in southern Italy.Cats can be carriers of infected arthropods and be infected with several vector-borne pathogens (VBP) but there is limited knowledge about their pathogenic role in cats.
1263 related Products with: Clinical evaluation of outdoor cats exposed to ectoparasites and associated risk for vector-borne infections in southern Italy.Oral squamous cell cancer Head & Neck cancer test t Recombinant Human Interfe Native Influenza HA (A To Native Influenza HA (A To Native Influenza HA (A To Cell Meter™ Fluorimetri Cell Meter™ Fluorimetri T-2 Toxin Mycotoxins ELIS Nycodenz, non ionic, non (7’-Benzyloxy-indolymet Homogenizer for 24 sample
#29524137 // Save this To Up
Stable Expression of Epigenome Editors via Viral Delivery and Genomic Integration.The advent of precise genomic targeting systems has revolutionized epigenome editing through fusion of epigenetic effector proteins with engineered DNA-binding proteins. However, the delivery of plasmid DNA to express these fusion proteins via conventional transient transfection has certain consequences which need to be considered during the experimental design. Transient transfection achieves peak gene expression between 24 and 96 h post-transfection after which the foreign gene is lost through cell division and degradation. The use of cell lines stably expressing the effector fusion protein of interest provides several advantages compared to standard transfection methods, and the most suitable means for creating these cell lines was found to be viral delivery followed by stable integration of the transgenes into the host genome. Here we describe a practical protocol to generate murine cell lines stably expressing fusion proteins of chromatin regulators and DNA-binding proteins using a retroviral murine stem cell virus (MSCV)-based vector system.
1403 related Products with: Stable Expression of Epigenome Editors via Viral Delivery and Genomic Integration.Recombinant Viral Antige Recombinant Viral antige Recombinant Viral antige Recombinant Viral antige Recombinant Viral antige Recombinant Viral antige Recombinant Viral antige Recombinant Viral Antige Viral antibodies, anti-R DNA (cytosine 5) methyltr Viral antibodies: anti-H Viral antibodies, anti-H
#29524011 // Save this To Up
HIVprotI: an integrated web based platform for prediction and design of HIV proteins inhibitors.A number of anti-retroviral drugs are being used for treating Human Immunodeficiency Virus (HIV) infection. Due to emergence of drug resistant strains, there is a constant quest to discover more effective anti-HIV compounds. In this endeavor, computational tools have proven useful in accelerating drug discovery. Although methods were published to design a class of compounds against a specific HIV protein, but an integrated web server for the same is lacking. Therefore, we have developed support vector machine based regression models using experimentally validated data from ChEMBL repository. Quantitative structure activity relationship based features were selected for predicting inhibition activity of a compound against HIV proteins namely protease (PR), reverse transcriptase (RT) and integrase (IN). The models presented a maximum Pearson correlation coefficient of 0.78, 0.76, 0.74 and 0.76, 0.68, 0.72 during tenfold cross-validation on ICand percent inhibition datasets of PR, RT, IN respectively. These models performed equally well on the independent datasets. Chemical space mapping, applicability domain analyses and other statistical tests further support robustness of the predictive models. Currently, we have identified a number of chemical descriptors that are imperative in predicting the compound inhibition potential. HIVprotI platform ( http://bioinfo.imtech.res.in/manojk/hivproti ) would be useful in virtual screening of inhibitors as well as designing of new molecules against the important HIV proteins for therapeutics development.
2179 related Products with: HIVprotI: an integrated web based platform for prediction and design of HIV proteins inhibitors.Recombinant HIV-1 Antigen HIV-1 Antigen Strain IIIB Recombinant Human Androge HIV 1 tat recombinant ant HIV 1 gag p24 recombinant HIV 1 nef recombinant ant HIV 1 env gp41 recombinan HIV 2 env gp36 recombinan HIV 1 p17 p24 recombinant Recombinant Viral Antige Recombinant Viral antige HIV 1 p24 core recombinan
#29523881 // Save this To Up
In vivo selection with lentiviral expression of Bcl2mutant in hematopoietic stem cell-transplanted mice.Current in vivo selections for hematopoietic stem cell (HSC)-based gene therapy are drug dependent and not without risk of cytotoxicity or tumorigenesis. We developed a new in vivo selection system with the non-phosphorylatable Bcl2 mutant Bcl2(Bcl2), which makes in vivo selection drug independent and without risk of cytotoxicity or tumorigenesis. We demonstrated in HSC-transplanted mice that Bcl2facilitated efficient in vivo selection in the absence of any exogenously applied drugs under both myeloablative and non-myeloablative conditioning. In mice transplanted with retrovirally transduced sca-1-positive bone marrow cells, the marked cell level increased from 26.38% of input transduced cells to 92.61 ± 0.95% of peripheral blood cells for myeloablative transplantation or to 37.82 ± 6.35% for non-myeloablative transplantation 6 months after transplantation. Bcl2did not induce tumorigenesis and does not influence hematopoiesis and the function of the reconstituted blood system. However, the high-level constitutive expression of Bcl2mediated by retroviral vector induced exhaustion of the marked cells after tertiary transplantation. Fortunately, low-level constitutive expression of Bcl2driven by an internal promoter in lentiviral vector could both maintain the marked cell level (24.13 ± 5.27%, 27.17 ± 5.51%, 24.33 ± 5.08%, and 22.07 ± 4.44% for primary, secondary, tertiary, and quaternary recipients) and avoid the exhaustion of the marked cells even in quaternary recipients. Importantly, the low-level constitutive expression of Bcl2did not induce tumorigenesis. Thus, the in vivo selection employing the low-level constitutive expression of Bcl2provides a general platform which is relevant for widespread applications of gene therapy.
1737 related Products with: In vivo selection with lentiviral expression of Bcl2mutant in hematopoietic stem cell-transplanted mice.DiscoveryPak™ Stem Cell pCAMBIA0105.1R Vector, (G DNA (cytosine 5) methyltr Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu Jurkat Cell Extract (Indu Macrophage Colony Stimula Macrophage Colony Stimula Stat3 Peptide Inhibitor, Stat3 Peptide Inhibitor, Cell Meter™ Intracellul
#29469452 // Save this To Up
[Preparation of recombinant retrovirus pRevTRE-E77.43 and its protective effect in a mouse model ofinfection].To explore the biological functions of E77.43, a gene segment of, in treatinginfection.
2662 related Products with: [Preparation of recombinant retrovirus pRevTRE-E77.43 and its protective effect in a mouse model ofinfection].Interleukins Recombinant Interleukins Recombinant HIV 1 gag p24 recombinant Anti AGO2 Mouse, Monoclon Anti AGO2 Mouse, Monoclon anti FAS IgG1 (monoclonal HIV1 integrase antibody, Goat Anti-Mouse SAR1, (in Goat Anti-Mouse Rab17 (mo Goat Anti-Mouse IA2, (int Goat Anti-Human, Mouse HI Goat Anti-Human FTO (Mous
#29468521 // Save this To Up
Identification of a Constitutively Active Mutant Mouse IRAK2 by Retroviral Expression Screening.To identify the importance of IRAK2 kinase activity in TLR-mediated signaling pathways, we constructed a retroviral vector harboring either a mouse IRAK2 gene (IRAK2-WT) or with its mutant with loss of function of its ATP-binding site (IRAK2-KD). Further, we comparatively analyzed for the gain of function and modulations in TLR-mediated signaling pathways in IRAK2 knockout (IRAK2-KO) macrophages upon introduction of the IRAK2-WT retroviral constructs. The pBS/IRAK2-KD with the ATP-binding site mutation in IRAK2 was obtained by using site-specific mutagenesis. The recombinants were identified with appropriate double digestion and sequence analysis. The recombinant vector constructs were transfected by lipofection into phoenix packaging cells. The viral vectors (10 cfu/mL) with the construct were allowed to infect IRAK2-KO macrophages. The results showed that IRAK2-WT gene overexpressed in the IRAK2-KO macrophages exhibited a modified IRAK2 expression upon LPS induction. However, the modification was absent with IRAK2-KD construct on LPS stimulation; instead, the IRAK2 protein stability was reduced considerably. The results further show that the LPS-induced effect on the stability of IRAK2 is dependent of IRAK4 stimulation.
1214 related Products with: Identification of a Constitutively Active Mutant Mouse IRAK2 by Retroviral Expression Screening.DNA (cytosine 5) methyltr Active Mouse Caspase 1100 Active Mouse Caspase 125 Active Mouse Caspase 3100 Active Mouse Caspase 325 Active Mouse Caspase 8100 Active Mouse Caspase 825 Mouse Anti-Human Matrix M Mouse L-308 Array, Glass Mouse L-308 Array, Glass Mouse L-308 Array, Membra Mouse L-308 Array, Membra
#29443638 // Save this To Up
Human Papillomavirus 16 E6 Induces FoxM1B in Oral Keratinocytes through GRHL2.High-risk human papillomavirus (HPV) is a major risk factor for oral and pharyngeal cancers (OPCs), yet the detailed mechanisms by which HPV promotes OPCs are not understood. Forkhead box M1B (FoxM1B) is an oncogene essential for cell cycle progression and tumorigenesis, and it is aberrantly overexpressed in many tumors. We previously showed that FoxM1B was the putative target of an epithelial-specific transcription factor, Grainyhead-like 2 (GRHL2). In the current study, we demonstrate that HPV type 16 (HPV-16) E6 induces FoxM1B in human oral keratinocytes (HOKs) and tonsillar epithelial cells (TECs) in part through GRHL2. FoxM1B was barely detectable in cultured normal human oral keratinocytes (NHOKs) and progressively increased in immortalized HOKs harboring HPV-16 genome (HOK-16B) and tumorigenic HOK-16B/BaP-T cells. Retroviral expression of HPV-16 E6 and/or E7 in NHOKs, TECs, and hypopharyngeal carcinoma cells (FaDu) revealed induction of FoxM1B and GRHL2 by the E6 protein but not E7. Both GRHL2 and FoxM1B were strongly induced in the epidermis of HPV-16 E6 transgenic mice and HPVoral squamous cell carcinomas. Ectopic expression of FoxM1B led to acquisition of transformed phenotype in HOK-16B cells. Loss of FoxM1B by lentiviral short hairpin RNA vector or chemical inhibitor led to elimination of tumorigenic characteristics of HOK-16B/BaP-T cells. Luciferase reporter assay revealed that GRHL2 directly bound and regulated the FoxM1B gene promoter activity. Using epithelial-specific Grhl2 conditional knockout mice, we exposed wild-type (WT) and Grhl2 KO mice to 4-nitroquinolin 1-oxide (4-NQO), which led to induction of FoxM1B in the tongue tissues and rampant oral tumor development in the WT mice. However, 4-NQO exposure failed to induce tongue tumors or induction of FoxM1B expression in Grhl2 KO mice. Collectively, these results indicate that HPV-16 induces FoxM1B in part through GRHL2 transcriptional activity and that elevated FoxM1B level is required for oropharyngeal cancer development.
1523 related Products with: Human Papillomavirus 16 E6 Induces FoxM1B in Oral Keratinocytes through GRHL2.Human Interleukin-16 IL-1 Recombinant Human Interle Recombinant Human Interle Inflammation (Human) Quan Inflammation (Human) Quan Inflammation (Human) Quan Goat Anti-Human GOT1 (aa Anti AGO2 Human, Monoclon Anti AGO2 Human, Monoclon CELLKINES Natural Human I Human Interleukin-4 IL-4 Human Interleukin-6 IL-6
#29441510 // Save this To Up
Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa.The combination of gene therapy and tissue engineering is one of the most promising strategies for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a rare genetic disease characterised by mutations in the COL7A1 gene, encoding type VII collagen (COLVII), which forms anchoring fibrils at the dermal-epidermal junction of the skin. This disease causes severe blistering and only palliative treatments are offered. In this study, the base of a strategy combining gene therapy and a tissue-engineered skin substitute (TES), which would be suitable for the permanent closure of skin wounds, was set-up. As a high transduction efficiency into fibroblasts and/or keratinocytes seems to be a prerequisite for a robust and sustained correction of RDEB, different envelope pseudotyped retroviral vectors and the transduction enhancer EF-C were tested. When green fluorescent protein (GFP) was used as a reporter gene to evaluate the retroviral-mediated gene transfer, the fibroblast infection efficiency was 30 % higher with the Ampho pseudotyped vector as compared with the other pseudotypes. At least a 3.1-fold and a 1.3-fold increased transduction were obtained in fibroblasts and keratinocytes, respectively, with EF-C as compared with polybrene. A continuous and intense deposit of haemagglutinin (HA)-COLVII was observed at the dermal-epidermal junction of self-assembled TESs made of cells transduced with a HA-tagged COL7A1 vector. Furthermore, HA-tagged basal epidermal cells expressing keratin 19 were observed in TESs, suggesting stem cell transduction. This approach could be a valuable therapeutic option to further develop, in order to improve the long-term life quality of RDEB patients.
1688 related Products with: Translating the combination of gene therapy and tissue engineering for treating recessive dystrophic epidermolysis bullosa.Stomach adenocarcinoma (c Stomach adenocarcinoma (c Stomach adenocarcinoma (c Esophagus squamous carcin Esophagus squamous cell c Esophagus squamous cell c Liver carcinoma (combinat Non small cell lung carci Colon adenocarcinoma (com Colon adenocarcinoma (com Colon adenocarcinoma (com Rectum carcinoma (combina
#29433935 // Save this To Up
Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.Loss of adenosine deaminase activity leads to severe combined immunodeficiency (ADA-SCID); production and function of T, B, and natural killer (NK) cells are impaired. Gene therapy (GT) with an autologous CD34-enriched cell fraction that contains CD34cells transduced with a retroviral vector encoding the human ADA cDNA sequence leads to immune reconstitution in most patients. Here, we report short- and medium-term safety analyses from 18 patients enrolled as part of single-arm, open-label studies or compassionate use programs. Survival was 100% with a median of 6.9 years follow-up (range, 2.3 to 13.4 years). Adverse events were mostly grade 1 or grade 2 and were reported by all 18 patients following GT. Thirty-nine serious adverse events (SAEs) were reported by 15 of 18 patients; no SAEs were considered related to GT. The most common adverse events reported post-GT include upper respiratory tract infection, gastroenteritis, rhinitis, bronchitis, oral candidiasis, cough, neutropenia, diarrhea, and pyrexia. Incidence rates for all of these events were highest during pre-treatment, treatment, and/or 3-month follow-up and then declined over medium-term follow-up. GT did not impact the incidence of neurologic/hearing impairments. No event indicative of leukemic transformation was reported.
1928 related Products with: Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.Adenosine Deaminase antib Primary antibody FLIP An LIVER DISEASES Adenosine PERMANENT AQUEOUS MOUNTIN Goat Anti-Human Androgen Goat Anti- Adenosine A1 r Goat Anti-Rhesus Adenosin Goat Anti-Human Adenosine Anti-Adenosine Deaminase Anti-Adenosine Deaminase Anti-Adenosine Deaminase Anti-Adenosine Deaminase
#29428935 // Save this To Up
MiR-124 Promotes the Growth of Retinal Ganglion Cells Derived from Müller Cells.Retinal Müller cells could be induced to differentiate into retinal ganglion cells (RGCs), but RGCs derived from Müller cells have defects in axon growth, leading to a defect in signal conduction. In this study we aimed to explore the role of miR-124 in axon growth of RGCs derived from Müller cells.
2344 related Products with: MiR-124 Promotes the Growth of Retinal Ganglion Cells Derived from Müller Cells.Epidermal Growth Factor ( Epidermal Growth Factor ( Human Retinal Microvascul GFP Expressing Human Reti RFP Expressing Human Reti Human Cord Blood CD34+ Ce LumiSTEM 96 iPS MSC deriv Fontana-Masson Stain Kit Fontana-Masson Stain Kit Anti C Reactive Protein A anti HSV (II) gB IgG1 (mo anti HCMV IE pp65 IgG1 (m
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 Fax 0032 16 50 90 45
9, rue Lagrange, 75005 Paris
Tel 01 43 25 01 50 Fax 01 43 25 01 60
52062 Aachen Deutschland
Tel 0241 40 08 90 86 Fax 0241 55 91 05 36
Howard Frank Turnberry House
1404-1410 High Road
Whetstone London N20 9BH
Tel 020 3393 8531 Fax 020 8445 9411
Schweiz Züri +41435006251
Česká republika Praha +420246019719
Ireland Dublin +35316526556
Norge Oslo +4721031366
Finland Helsset +358942419041
Sverige Stockholm +46852503438
Ελλάς Αθήνα +302111768494
Magyarország Budapest +3619980547
GENTAUR Poland Sp. z o.o.
ul. Grunwaldzka 88/A m.2
81-771 Sopot, Poland
Tel 058 710 33 44
Fax 058 710 33 48
GENTAUR Nederland BV
5521 DG Eersel Nederland
Tel 0208-080893 Fax 0497-517897
Piazza Giacomo Matteotti, 6, 24122 Bergamo
Tel 02 36 00 65 93 Fax 02 36 00 65 94
53 Iskar Str. 1191 Kokalyane, Sofia